Topical TYK2 inhibitor ameliorates psoriasis-like dermatitis via the AKT-SP1-NGFR-AP1 pathway in keratinocytes

Zhiqin Fang; Rundong Jiang; Yutong Wang; Wangqing Chen; Xiang Chen; Mingzhu Yin

doi:10.1002/ctm2.70256

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (3) : e70256 DOI: 10.1002/ctm2.70256

RESEARCH ARTICLE

Topical TYK2 inhibitor ameliorates psoriasis-like dermatitis via the AKT-SP1-NGFR-AP1 pathway in keratinocytes

Zhiqin Fang ¹^,²
, Rundong Jiang ¹^,²^,³
, Yutong Wang ¹^,⁴
, Wangqing Chen ¹^,²
, Xiang Chen ¹^,²^,^†
, Mingzhu Yin ¹^,²^,⁵^,^†

Author information +

History +

PDF

Abstract

	•Topical TYK2 inhibitor alleviates psoriasis-like dermatitis.
	•Topical TYK2 inhibitor reduces psoriasis progression through restraining the inflammatory responses of keratinocytes.
	•The inhibition of TYK2 regulates the inflammatory response of keratinocytes through AKT-SP1-NGFR-AP1 pathway.

Keywords

inflammatory response / keratinocyte / psoriasis / topical treatment / TYK2 inhibitor

Cite this article

Download citation ▾

Zhiqin Fang,Rundong Jiang,Yutong Wang,Wangqing Chen,Xiang Chen,Mingzhu Yin. Topical TYK2 inhibitor ameliorates psoriasis-like dermatitis via the AKT-SP1-NGFR-AP1 pathway in keratinocytes. Clinical and Translational Medicine, 2025, 15(3): e70256 DOI:10.1002/ctm2.70256

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.